Cancer

June 15, 2017

Combination therapy for enhancing the efficacy of tyrosine-kinase inhibitor (TKI) in BCR-ABL-induced Human leukemia: A therapeutic mix encompassing Ascorbate and Forodesine decreases the expression of oncoproteins c-FOS, DUSP1 and BCR-ABL, inhibits TKI resistance, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and cure CML and kinase-driven cancers via up-regulation of its target gene, 16/June/2017, 2.05 am

Introduction: What they say: A study from the Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Division of Pathology, Cincinnati Children’s Hospital […]
June 15, 2017

Interleukin therapy for Chronic Myeloid leukaemia (CML): Interleukin-1β decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 15/June/2017, 11.48 pm

Introduction: What they say: A study from the Department of Biochemistry-Molecular Biology, Franklin College of Arts and Sciences, The University of Georgia, Athens, Georgia 30602, USA; […]
June 14, 2017

Natural product-derived Anti-AXL therapeutics for enhancing the efficacy of chemotherapies: Combination of Honokiol and Hesperidin, found in Magnolia grandiflora and Citrus fruits, respectively, decreases the expression of the AXL receptor and its activating ligand, GAS6, increases the expression of a number of tumor suppressor genes, increases therapeutic index of anticancer drugs, suppresses tumorigenesis, migration, invasion, and metastasis via up regulation of its target gene, 15/June/2017, 1.00 am

Introduction: What they say: A study from the Department of Radiation Oncology, Stanford University School of Medicine shows that “Inhibition of the GAS6/AXL pathway augments the […]
June 13, 2017

Molecular therapy for Chronic Myeloid leukaemia (CML): Resistin decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 13/June/2017, 11.59 p

Introduction: What they say: A study from the Department of Biochemistry-Molecular Biology, Franklin College of Arts and Sciences, The University of Georgia, Athens, Georgia 30602, USA; […]